Advertisement
Advertisement
U.S. markets open in 7 hours 33 minutes
S&P Futures
4,151.00 +9.25 (+0.22%) Dow Futures
32,860.00 +68.00 (+0.21%) Nasdaq Futures
13,212.00 +28.75 (+0.22%) Russell 2000 Futures
1,946.00 +4.90 (+0.25%) Crude Oil
90.84 +0.08 (+0.09%) Gold
1,803.30 -1.90 (-0.11%)
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 47.11 |
| Open | 47.74 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1200 |
| Day's Range | 47.50 - 49.77 |
| 52 Week Range | 39.41 - 127.97 |
| Volume | |
| Avg. Volume | 523,806 |
| Market Cap | 1.733B |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.90 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.33 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for NVRO
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Nevro Corp.Analyst Report: Insulet CorporationInsulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide.RatingFair ValueEconomic Moat4 days agoMorningstar
- Zacks
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
- Zacks
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
